Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia

Maiko Matsushita, Hideyuki Ikeda, Masahiro Kizaki, Shinichiro Okamoto, Masahiro Ogasawara, Yasuo Ikeda, Yutaka Kawakami

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

PRAME (Preferentially expressed antigen of melanoma) has been previously identified as a melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a variety of cancer cells including leukaemic cells. We have screened 98 Japanese patients with leukaemia and lymphoma for expression of the PRAME gene using semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Forty-one patients (42%) showed high levels of PRAME expression. Eight of these patients were then monitored using real-time PCR for a period of 10-37 months. Significant reductions in the PRAME expression were observed in all patients after chemotherapy. An increased expression was detected in the two patients who relapsed, one of which was before cytological diagnosis. These changes were correlated with those of other known genetic markers, such as the bcr-abl gene. Therefore, quantitative monitoring of the PRAME gene using real-time PCR method may be useful for detecting minimal residual disease and to predict subsequent relapse, especially in patients without known genetic markers. In addition, a PRAME-positive leukaemia cell line and fresh leukaemic cells were found to be susceptible to lysis by PRAME-specific CTLs established from a patient with melanoma, suggesting that the PRAME peptide can also be a target leukaemia antigen for T cells.

Original languageEnglish
Pages (from-to)916-926
Number of pages11
JournalBritish Journal of Haematology
Volume112
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Melanoma-Specific Antigens
Residual Neoplasm
Leukemia
Genes
Genetic Markers
Real-Time Polymerase Chain Reaction
abl Genes
T-Lymphocytes
Reverse Transcription
Melanoma
Lymphoma
Recurrence
Drug Therapy
Cell Line
Polymerase Chain Reaction
Peptides

Keywords

  • Cytotoxic T cell
  • Minimal residual disease
  • PRAME
  • Real-time PCR
  • Tumour antigen

ASJC Scopus subject areas

  • Hematology

Cite this

Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. / Matsushita, Maiko; Ikeda, Hideyuki; Kizaki, Masahiro; Okamoto, Shinichiro; Ogasawara, Masahiro; Ikeda, Yasuo; Kawakami, Yutaka.

In: British Journal of Haematology, Vol. 112, No. 4, 2001, p. 916-926.

Research output: Contribution to journalArticle

Matsushita, Maiko ; Ikeda, Hideyuki ; Kizaki, Masahiro ; Okamoto, Shinichiro ; Ogasawara, Masahiro ; Ikeda, Yasuo ; Kawakami, Yutaka. / Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. In: British Journal of Haematology. 2001 ; Vol. 112, No. 4. pp. 916-926.
@article{8fdcc29d794246e68d3997264ef1be56,
title = "Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia",
abstract = "PRAME (Preferentially expressed antigen of melanoma) has been previously identified as a melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a variety of cancer cells including leukaemic cells. We have screened 98 Japanese patients with leukaemia and lymphoma for expression of the PRAME gene using semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Forty-one patients (42{\%}) showed high levels of PRAME expression. Eight of these patients were then monitored using real-time PCR for a period of 10-37 months. Significant reductions in the PRAME expression were observed in all patients after chemotherapy. An increased expression was detected in the two patients who relapsed, one of which was before cytological diagnosis. These changes were correlated with those of other known genetic markers, such as the bcr-abl gene. Therefore, quantitative monitoring of the PRAME gene using real-time PCR method may be useful for detecting minimal residual disease and to predict subsequent relapse, especially in patients without known genetic markers. In addition, a PRAME-positive leukaemia cell line and fresh leukaemic cells were found to be susceptible to lysis by PRAME-specific CTLs established from a patient with melanoma, suggesting that the PRAME peptide can also be a target leukaemia antigen for T cells.",
keywords = "Cytotoxic T cell, Minimal residual disease, PRAME, Real-time PCR, Tumour antigen",
author = "Maiko Matsushita and Hideyuki Ikeda and Masahiro Kizaki and Shinichiro Okamoto and Masahiro Ogasawara and Yasuo Ikeda and Yutaka Kawakami",
year = "2001",
doi = "10.1046/j.1365-2141.2001.02670.x",
language = "English",
volume = "112",
pages = "916--926",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia

AU - Matsushita, Maiko

AU - Ikeda, Hideyuki

AU - Kizaki, Masahiro

AU - Okamoto, Shinichiro

AU - Ogasawara, Masahiro

AU - Ikeda, Yasuo

AU - Kawakami, Yutaka

PY - 2001

Y1 - 2001

N2 - PRAME (Preferentially expressed antigen of melanoma) has been previously identified as a melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a variety of cancer cells including leukaemic cells. We have screened 98 Japanese patients with leukaemia and lymphoma for expression of the PRAME gene using semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Forty-one patients (42%) showed high levels of PRAME expression. Eight of these patients were then monitored using real-time PCR for a period of 10-37 months. Significant reductions in the PRAME expression were observed in all patients after chemotherapy. An increased expression was detected in the two patients who relapsed, one of which was before cytological diagnosis. These changes were correlated with those of other known genetic markers, such as the bcr-abl gene. Therefore, quantitative monitoring of the PRAME gene using real-time PCR method may be useful for detecting minimal residual disease and to predict subsequent relapse, especially in patients without known genetic markers. In addition, a PRAME-positive leukaemia cell line and fresh leukaemic cells were found to be susceptible to lysis by PRAME-specific CTLs established from a patient with melanoma, suggesting that the PRAME peptide can also be a target leukaemia antigen for T cells.

AB - PRAME (Preferentially expressed antigen of melanoma) has been previously identified as a melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a variety of cancer cells including leukaemic cells. We have screened 98 Japanese patients with leukaemia and lymphoma for expression of the PRAME gene using semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Forty-one patients (42%) showed high levels of PRAME expression. Eight of these patients were then monitored using real-time PCR for a period of 10-37 months. Significant reductions in the PRAME expression were observed in all patients after chemotherapy. An increased expression was detected in the two patients who relapsed, one of which was before cytological diagnosis. These changes were correlated with those of other known genetic markers, such as the bcr-abl gene. Therefore, quantitative monitoring of the PRAME gene using real-time PCR method may be useful for detecting minimal residual disease and to predict subsequent relapse, especially in patients without known genetic markers. In addition, a PRAME-positive leukaemia cell line and fresh leukaemic cells were found to be susceptible to lysis by PRAME-specific CTLs established from a patient with melanoma, suggesting that the PRAME peptide can also be a target leukaemia antigen for T cells.

KW - Cytotoxic T cell

KW - Minimal residual disease

KW - PRAME

KW - Real-time PCR

KW - Tumour antigen

UR - http://www.scopus.com/inward/record.url?scp=0035053071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035053071&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02670.x

DO - 10.1046/j.1365-2141.2001.02670.x

M3 - Article

C2 - 11298586

AN - SCOPUS:0035053071

VL - 112

SP - 916

EP - 926

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -